Equities Analysts Offer Predictions for Icon FY2025 Earnings

Key Points

• Leerink Partners has downgraded their earnings forecast for Icon Plc, projecting FY2025 earnings at $12.67 per share, down from a prior estimate of $12.79.
• While Leerink has a negative outlook, other analysts have revised their price targets upwards; Mizuho, Truist, and Evercore ISI raised their targets significantly, indicating a divided analyst consensus on Icon's stock.
• Icon's stock is currently trading at $175.82, with a market capitalization of $14.20 billion and a recent earnings report showing a decline in revenue compared to the same quarter last year.

Icon Plc (NASDAQ:ICLR - Free Report) - Leerink Partnrs lowered their FY2025 earnings estimates for Icon in a report issued on Tuesday, August 12th. Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will post earnings of $12.67 per share for the year, down from their previous estimate of $12.79. The consensus estimate for Icon's current full-year earnings is $13.38 per share. Leerink Partnrs also issued estimates for Icon's FY2026 earnings at $13.51 EPS, FY2027 earnings at $15.57 EPS and FY2028 earnings at $17.28 EPS.

Icon (NASDAQ:ICLR - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $3.26 EPS for the quarter, topping the consensus estimate of $3.18 by $0.08. Icon had a net margin of 9.82% and a return on equity of 10.95%. The firm had revenue of $2.02 billion for the quarter, compared to the consensus estimate of $1.98 billion. During the same quarter in the previous year, the firm earned $3.75 earnings per share. The company's quarterly revenue was down 4.8% compared to the same quarter last year. Icon has set its FY 2025 guidance at 13.000-14.000 EPS.

Other research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. cut shares of Icon from an "overweight" rating to a "neutral" rating and cut their price target for the stock from $265.00 to $150.00 in a report on Tuesday, April 29th. Barclays upped their price objective on shares of Icon from $155.00 to $180.00 and gave the stock an "equal weight" rating in a research note on Friday, July 25th. Mizuho upped their price objective on shares of Icon from $173.00 to $225.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. The Goldman Sachs Group decreased their price target on shares of Icon from $180.00 to $160.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Finally, Robert W. Baird raised shares of Icon from a "neutral" rating to an "outperform" rating and increased their price target for the company from $150.00 to $224.00 in a research report on Thursday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $219.54.

Icon Price Performance

ICLR traded up $0.61 during trading hours on Friday, hitting $180.25. The company's stock had a trading volume of 987,561 shares, compared to its average volume of 1,310,575. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.35. Icon has a 12 month low of $125.10 and a 12 month high of $328.35. The stock has a market cap of $14.56 billion, a price-to-earnings ratio of 18.54, a P/E/G ratio of 2.64 and a beta of 1.17. The business's 50-day moving average price is $157.62 and its 200-day moving average price is $159.91.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ICLR. Artisan Partners Limited Partnership raised its holdings in shares of Icon by 67.4% during the 2nd quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company's stock worth $1,045,039,000 after acquiring an additional 2,893,946 shares during the period. Harris Associates L P acquired a new position in Icon in the 2nd quarter valued at about $238,256,000. Norges Bank acquired a new position in Icon in the 2nd quarter valued at about $158,639,000. 1832 Asset Management L.P. grew its position in shares of Icon by 587.9% during the second quarter. 1832 Asset Management L.P. now owns 1,151,328 shares of the medical research company's stock worth $167,461,000 after buying an additional 983,950 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Icon during the second quarter worth about $94,814,000. Hedge funds and other institutional investors own 95.61% of the company's stock.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.